Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | APLNR | P35414 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL659089 | 1.00 | APLNR (0.32) | APLNR | |
| SCHEMBL466077 | 1.00 | APLNR (0.32) | APLNR | |
| Hydrochloric Acid SCHEMBL907538 | 0.98 | APLNR (0.31) | APLNR | |
| Hydrochloric Acid SCHEMBL907061 | 0.98 | APLNR (0.31) | APLNR | |
| Hydrochloric Acid SCHEMBL907063 | 0.98 | APLNR (0.31) | APLNR | |
| SCHEMBL27759741 | 0.84 | DPP4 (0.31) | APLNR | |
| SCHEMBL25628552 | 0.83 | — | — | |
| SCHEMBL25633183 | 0.83 | DPP4 (0.33) | APLNR | |
| SCHEMBL22961474 | 0.77 | — | — | |
| SCHEMBL23055377 | 0.74 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 120 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9453017-B2 | Antiviral therapies with phospholipase D inhibitors | VANDERBILT UNIVERSITY (US) | 2016-09-27 | — | — | US | claimed |
| EP-2277850-A1 | 1-amino-alkylcyclohexanes as 5-HT3 and neuronal nicotinic receptor antagonists | Merz Pharma GmbH & Co. KGaA (DE) | 2011-01-26 | — | — | EP | claimed |
| EP-2260839-A2 | Combination therapy using 1-aminocyclohexane derivatives and acetylcholinesterase inhibitors | Merz Pharma GmbH & Co. KGaA (DE) | 2010-12-15 | — | — | EP | claimed |
| US-20100298442-A1 | 1-Amino-alkyl-cyclohexanes as 5-HT3 and neuronal nicotinic receptor antagonists | MERZ PHARMA GMBH & CO. KGAA (DE) | 2010-11-25 | — | — | US | claimed |
| EP-1682109-B1 | THE USE OF 1-AMINOCYCLOHEXANE DERIVATIVES TO MODIFY DEPOSITION OF FIBRILLOGENIC AS PEPTIDES IN AMYLOIDOPATHIES | MERZ PHARMA GMBH & CO KGAA (DE) | 2008-10-15 | — | — | EP | claimed |
| EP-1838297-A1 | 1-AMINOCYCLOHEXANE-DERIVATIVES FOR THE TREATMENT OF MULTIPLE SCLEROSIS EMOTIONAL LABILITY AND PSEUDOBULBAR AFFECT | Merz Pharma GmbH & Co. KGaA (DE) | 2007-10-03 | — | — | EP | claimed |
| US-20070105961-A1 | 1-Amino-alkylcyclohexanes as 5-HT3 and neuronal nicotinic receptor antagonists | MERZ PHARMA GMBH & CO. KGAA (DE) | 2007-05-10 | — | — | US | claimed |
| US-20070082956-A1 | The use of 1-amino-alkylcyclohexane compounds in the treatment of pain hypersensitivity. | MERZ PHARMA GMBH & CO. KGAA (DE) | 2007-04-12 | — | — | US | claimed |
| US-20060205822-A1 | 1-Aminocyclohexane derivatives for the treatment of multiple sclerosis, emotional lability and pseudobulbar affect | FOREST LABORATORIES, INC. (US) | 2006-09-14 | — | — | US | claimed |
| EP-1682109-A1 | THE USE OF 1-AMINOCYCLOHEXANE DERIVATIVES TO MODIFY DEPOSITION OF FIBRILLOGENIC AS PEPTIDES IN AMYLOIDOPATHIES | Merz Pharma GmbH & Co. KGaA (DE) | 2006-07-26 | — | — | EP | claimed |
| WO-2006069294-A1 | 1-AMINOCYCLOHEXANE-DERIVATIVES FOR THE TREATMENT OF MULTIPLE SCLEROSIS EMOTIONAL LABILITY AND PSEUDOBULBAR AFFECT | MERZ PHARMA GMBH & CO. KGAA (DE) | 2006-06-29 | — | — | WO | claimed |
| EP-1660058-A2 | THE USE OF 1-AMINO-ALKYLCYCLOHEXANE COMPOUNDS IN THE TREATMENT OF PAIN HYPERSENSITIVITY | Merz Pharma GmbH & Co. KGaA (DE) | 2006-05-31 | — | — | EP | claimed |
| WO-2005079779-A1 | THE USE OF 1-AMINOCYCLOHEXANE DERIVATIVES TO MODIFY DEPOSITION OF FIBRILLOGENIC Aß PEPTIDES IN AMYLOIDOPATHIES | MERZ PHARMA GMBH & CO. KGAA (DE) | 2005-09-01 | — | — | WO | claimed |
| EP-1556019-A2 | COMBINATION THERAPY USING 1-AMINOCYCLOHEXANE DERIVATIVES AND ACETYLCHOLINESTERASE INHIBITORS | Merz Pharma GmbH & Co. KGaA (DE) | 2005-07-27 | — | — | EP | claimed |
| US-20050113458-A1 | delivering to said cell an 1-aminocyclohexane derivative; for decreasing the level of at least one amyloid peptide produced by a mammalian cell that expresses amyloid precursor protein | FOREST LABORATORIES, INC. (US) | 2005-05-26 | — | — | US | claimed |
| WO-2005009421-A2 | THE USE OF 1-AMINO-ALKYLCYCLOHEXANE COMPOUNDS IN THE TREATMENT OF PAIN HYPERSENSITIVITY | MERZ PHARMA GMBH & CO. KGAA (DE) | 2005-02-03 | — | — | WO | claimed |
| WO-2004037234-A2 | COMBINATION THERAPY USING 1-AMINOCYCLOHEXANE DERIVATIVES AND ACETYLCHOLINESTERASE INHIBITORS | MERZ PHARMA GMBH & CO. KGAA (DE) | 2004-05-06 | — | — | WO | claimed |
| US-20040087658-A1 | Synergistic mixture; Alzheimer's disease therapy | MERZ PHARMA GMBH & CO. KGAA (DE) | 2004-05-06 | — | — | US | claimed |
| US-20210169864-A1 | COMBINATION THERAPY USING 1-AMINOCYCLOHEXANE DERIVATIVES AND ACETYLCHOLINESTERASE INHIBITORS | MERZ PHARMA GMBH & CO KGAA (DE) | 2021-06-10 | — | — | US | disclosed |
| US-6602862-B1 | 1-Amino-alkylcyclohexanes as trypanocidal agents | MERZ PHARMA GMBH & CO., KGAA (DE) | 2003-08-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070082956-A1 | The use of 1-amino-alkylcyclohexane compounds in the treatment of pain hypersensitivity. | GRIN1, OPRL1, GRIN3A | APLNR 249/4885 |
| US-20210169864-A1 | COMBINATION THERAPY USING 1-AMINOCYCLOHEXANE DERIVATIVES AND ACETYLCHOLINESTERASE INHIBITORS | ACHE, PSEN1, BCHE | APLNR 2274/4885 |
| US-20070105961-A1 | 1-Amino-alkylcyclohexanes as 5-HT3 and neuronal nicotinic receptor antagonists | HTR3A, CHRNA3, HTR3B | APLNR 230/4885 |
| US-20050113458-A1 | delivering to said cell an 1-aminocyclohexane derivative; for decreasing the level of at least one amyloid peptide produced by a mammalian cell that expresses amyloid precursor protein | APP, BACE1, PSEN1 | APLNR 45/4885 |
| US-20100298442-A1 | 1-Amino-alkyl-cyclohexanes as 5-HT3 and neuronal nicotinic receptor antagonists | HTR3A, CHRNA3, HTR3B | APLNR 279/4885 |
| US-20060205822-A1 | 1-Aminocyclohexane derivatives for the treatment of multiple sclerosis, emotional lability and pseudobulbar affect | NMBR, NMUR1, CNR1 | APLNR 1929/4885 |
| US-20040087658-A1 | Synergistic mixture; Alzheimer's disease therapy | ACHE, BACE1, CHRNA5 | APLNR 849/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.